Zydus Cadila has received an approval from the US FDA to market Carvedilol Tablets 3.125 mg, 6.25 mg, 12.5 mg and 25 mg., in the US market. The drug falls in the Cardiovascular segment. The sales of Carvedilol Tablets in the US market as per NDC Health is estimated at USD 1.24 bn.
Gaining a significant advantage, Zydus Pharmaceuticals (USA) Inc., launched the product on the very first day after receiving approval from the USFDA.
The group now has 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs.
